Complement System Disorders - WHIM Syndrome - Xolremdi
Defines Cigna coverage and prior authorization criteria for Xolremdi (mavorixafor capsules) for treatment of WHIM syndrome in patients ≥12 years, including initial and continuation approval conditions, duration, prescribing specialist requirements, and non-covered uses.
New policy created.
Annual revision performed.
Coverage Summary
Defines Cigna coverage and prior authorization criteria for Xolremdi (mavorixafor capsules) for treatment of WHIM syndrome in patients ≥ 12 years, including initial and continuation approval conditions, duration, prescribing specialist requirements, and non-covered uses. Coverage is covered_with_criteria and approvals are provided for 1 year.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.